.

Cytokinetics traded at $48.45 this Friday September 30th, decreasing $0.48 or 0.98 percent since the previous trading session. Looking back, over the last four weeks, Cytokinetics lost 8.52 percent. Over the last 12 months, its price rose by 31.87 percent. Looking ahead, we forecast Cytokinetics to be priced at 49.28 by the end of this quarter and at 45.00 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
48.45
Daily Change
-0.98%
Yearly
31.87%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 7,749.00 45.00 0.58% -5.36%
Arca Biopharma 2.06 -0.08 -3.74% -30.64%
Acadia Pharmaceuticals 16.36 0.22 1.36% -6.41%
Acorda Therapeutics 0.30 0.02 8.06% -93.56%
Amgen 225.40 -3.01 -1.32% 5.37%
Bayer 47.42 -0.31 -0.64% 1.88%
Brainstorm Cell Therapeutics 4.42 0.25 6.00% 35.58%
Biogen 267.00 2.72 1.03% -5.97%
Bristol-Myers Squibb 71.09 -0.62 -0.86% 19.46%
Capricor Therapeutics 6.00 0.07 1.18% 51.13%
Cytokinetics 48.45 -0.48 -0.98% 31.87%
Exelixis 15.68 -0.16 -1.01% -27.21%
Geron 2.34 0.03 1.30% 69.57%
Genocea Biosciences 0.01 -0.003 -18.06% -99.41%
Halozyme Therapeutics 39.54 0.02 0.05% -2.97%
Ionis Pharmaceuticals 44.23 -0.05 -0.11% 31.75%
Intra Cellular Therapies 46.53 1.28 2.83% 20.98%
Ligand Pharmaceuticals 86.11 0.54 0.63% -36.13%
Eli Lilly 323.63 -6.66 -2.02% 40.96%
Merck & Co 86.12 -0.52 -0.60% 5.80%
Novartis 75.53 0.61 0.81% -0.70%
Pfizer 43.76 -0.40 -0.91% 1.93%
Regeneron Pharmaceuticals 688.87 -2.95 -0.43% 20.69%
Roche Holding 323.45 3.20 1.00% -6.31%
Sanofi 78.40 0.56 0.72% -5.10%

Indexes Price Day Year
USND 10576 -161.89 -1.51% -27.40%
US2000 1665 -10.21 -0.61% -25.74%

Cytokinetics
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.